Details

Autor(en) / Beteiligte

• Liu, Yibin
• Keib, Anna
• Neuber, Brigitte
• Wang, Lei
• Riemer, Angelika B
• Bonsack, Maria
• Hückelhoven-Krauss, Angela
• Schmitt, Anita
• Müller-Tidow, Carsten
• Schmitt, Michael

Titel

Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma

Ist Teil von

• International journal of molecular sciences, 2023-01, Vol.24 (3), p.1943

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• The transcription factor SOX11 is a tumor-associated antigen with low expression in normal cells, but overexpression in glioblastoma (GBM). So far, conventional surgery, chemotherapy, and radiotherapy have not substantially improved the dismal prognosis of relapsed/refractory GBM patients. Immunotherapy is considered a promising strategy against GBM, but there is a fervent need for better immunotargets in GBM. To this end, we performed an in silico prediction study on SOX11, which primarily yielded ten promising HLA-A*0201-restricted peptides derived from SOX11. We defined a novel peptide FMACSPVAL, which had the highest score according to in silico prediction (6.02 nM by NetMHC-4.0) and showed an exquisite binding affinity to the HLA-A*0201 molecule in the peptide-binding assays. In the IFN-γ ELISPOT assays, FMACSPVAL demonstrated a high efficiency for generating SOX11-specific CD8 T cells. Nine out of thirty-two healthy donors showed a positive response to SOX11, as assessed by the ELISPOT assays. Therefore, this novel antigen peptide epitope seems to be promising as a target for T cell-based immunotherapy in GBM. The adoptive transfer of in vitro elicited SOX11-specific CD8 T cells constitutes a potential approach for the treatment of GBM patients.